论文部分内容阅读
目的:评价恩替卡韦对乙型肝炎伴肝硬化患者的临床疗效。方法:选取2015年1月—2016年2月收治的乙型肝炎瘵肝硬化患者97例,按入院时间先后将其分为观察组43例和对照组44例;观察组患者给予恩替卡韦治疗,对照组患者给予拉米夫定治疗,评价两组患者治疗前后肝功能各指标变化情况、阴转率和变异率。结果:观察组患者治疗后血清乙肝病毒HBV-DNA低于对照组患者(P<0.05);观察组患者治疗后乙肝病毒HBV-DNA转阴率(90.70%)明显高于对照组(72.73%)(P<0.05),病毒变异率明显低于对照组(P<0.05)。结论:采用恩替卡韦治疗乙型肝炎伴肝硬化患者的效果较为显著,其疗效优于拉米夫定。
Objective: To evaluate the clinical efficacy of entecavir in patients with hepatitis B and liver cirrhosis. Methods: 97 patients with cirrhosis of hepatitis B cirrhosis who were admitted from January 2015 to February 2016 were divided into observation group (43 cases) and control group (44 cases) according to the time of admission. Patients in observation group were treated with entecavir Group patients were given lamivudine treatment, evaluation of two groups of patients before and after treatment of liver function indicators of change, negative conversion rate and mutation rate. Results: After treatment, the serum HBV-DNA of HBV in the observation group was lower than that in the control group (P <0.05). The HBV-DNA negative rate (90.70%) in the observation group was significantly higher than that in the control group (72.73% (P <0.05), and the virus mutation rate was significantly lower than that of the control group (P <0.05). Conclusion: The effect of entecavir treatment of hepatitis B patients with liver cirrhosis is more significant, its efficacy is better than lamivudine.